Oleanolic Acid, a Novel Endothelin A Receptor Antagonist, Alleviated High Glucose-Induced Cardiomyocytes Injury

Am J Chin Med. 2018;46(6):1187-1201. doi: 10.1142/S0192415X18500623. Epub 2018 Aug 27.

Abstract

Endothelin-1 (ET-1) and its receptor endothelin A receptor (ET[Formula: see text] have been shown to be upregulated in a high glucose environment, which increase the incidence of diabetes-related heart failure. Our previous study demonstrated that oleanolic acid (OA), a natural compound found in Chinese herbs had ET-1 antagonistic effects. We aimed to verify whether OA could ameliorate diabetes mellitus (DM)-induced injury in cardiomyocytes by reducing the antagonistic effects of the ET-1 pathway. For the induction of high glucose-related injury in cardiomyocytes, neonatal rat ventricular cardiomyocytes (NRVMs) were subjected to culture medium containing 25[Formula: see text]mM of glucose. Natriuretic peptide B (BNP), mitochondrial membrane potential (MMP) and cell surface area were measured to evaluate the severity of NRVMs injury. mRNA expression of ET-1 and ETA was determined using quantitative PCR. Moreover, a Ca[Formula: see text] influx assay was used to evaluate potential ETA antagonistic effects. Molecular docking of OA and ETA was performed using the Sulflex-Dock program. Human induced pluripotent stem cell (iPS-C)-derived cardiomyocytes and real time cell analysis system (RTCA) were used to verify the effect of OA on the ET-1 pathway. High glucose levels increased the expression of BNP at both mRNA and protein levels in cardiomyocytes. Moreover, cell surface area and MMP were also elevated in a high glucose environment. High glucose-induced injury in NRVMs was not reversible by hypoglycemic therapy. In addition, ETA was upregulated by high glucose treatment and levels could not be reduced by hypoglycemic treatment. The Ca[Formula: see text] influx assay on ETA/HEK293 cells showed that OA had a partial ETA antagonistic effect. Molecular docking approaches showed that OA was docked into the active site of ETA. Furthermore, functionality tests based on iPS-C and RTCA demonstrated that treatment with OA could reverse ET-1-induced alternation of beating rates and amplitude. Thus, OA could reverse high glucose-induced BNP upregulation, and increased both the cell area and MMP in NRVMs. High glucose-induced irreversible ETA upregulation is a major reason of continuous diabetes-related injury in cardiomyocytes. Treatment with OA had a protective effect on high glucose-induced injury in cardiomyocytes through a partial ETA antagonistic role.

Keywords: Endothelin A Receptor; Endothelin-1; High Glucose Induced Cardiomyocytes Damage; Oleanolic Acid.

MeSH terms

  • Animals
  • Diabetes Complications*
  • Endothelin A Receptor Antagonists*
  • Female
  • Glucose / adverse effects*
  • HEK293 Cells
  • Heart Failure / etiology*
  • Heart Failure / prevention & control
  • Humans
  • Male
  • Membrane Potential, Mitochondrial
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology*
  • Natriuretic Peptide, Brain / metabolism
  • Oleanolic Acid / pharmacology*
  • Oleanolic Acid / therapeutic use
  • Phytotherapy
  • Rats, Sprague-Dawley
  • Up-Regulation / drug effects

Substances

  • Endothelin A Receptor Antagonists
  • Natriuretic Peptide, Brain
  • Oleanolic Acid
  • Glucose